{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "STX.L",
  "generated_at": "2026-01-12T05:21:37.358873Z",
  "top_card": {
    "ticker": "STX.L",
    "company_name": "Shield Therapeutics plc",
    "sector": "Healthcare",
    "market_cap_gbp": 112121966,
    "days_active": 543,
    "apex_score_100": 60,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "CROWDED",
    "action": "SELL/TAKE_PROFITS",
    "thesis_one_liner": "SELL/TAKE_PROFITS - CROWDED timing with 60/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Shield Therapeutics plc",
      "sector": "Healthcare",
      "industry": "Drug Manufacturers - Specialty & Generic",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 112121966,
      "current_close_price": 10.5
    },
    "basics": {
      "ticker": "STX.L",
      "current_price": 10.5,
      "ath": 184.8142,
      "atl": 1.063,
      "ath_date": "2020-01-08",
      "atl_date": "2024-04-25",
      "week_52_high": 12.5,
      "week_52_low": 2.1,
      "week_52_high_date": "2025-12-04",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 94.32,
      "data_start": "2020-01-02",
      "data_end": "2026-01-09",
      "total_bars": 1521
    },
    "latest_signal": {
      "date": "2024-07-15",
      "scan_date": "2026-01-09",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.6,
      "drawdown_pct": 87.55,
      "ai_score": 9.0,
      "rsi": 18.2,
      "cycle_position": 0.1818,
      "holding_period_days": 543,
      "current_pnl_pct": 556.25,
      "rally_state": "rallying",
      "distance_from_high_pct": -11.02,
      "Rally_Count": 1,
      "days_since_last_high": 24,
      "last_high_date": "2025-12-18",
      "lock_in_reached": true,
      "lock_in_date": "2025-12-03",
      "best_rally_pct": 637.5
    },
    "best_historical_signal": {
      "signal_date": "2024-04-25",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 1.225,
      "peak_price": 12.5,
      "peak_date": "2025-12-04",
      "rally_pct": 920.41,
      "days_to_peak": 588,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "STX.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.5,
        "current_return_pct": 44.12,
        "best_rally_pct": 75.33,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -17.8,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1291,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.5,
        "current_return_pct": 39.47,
        "best_rally_pct": 69.68,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -17.8,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1290,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5085,
        "current_price": 10.5,
        "current_return_pct": 61.33,
        "best_rally_pct": 96.27,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -17.8,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1287,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.3628,
        "current_price": 10.5,
        "current_return_pct": 65.02,
        "best_rally_pct": 100.76,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 6,
        "distance_from_high_pct": -17.8,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1286,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.2414,
        "current_price": 10.5,
        "current_return_pct": 68.23,
        "best_rally_pct": 104.67,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 5,
        "distance_from_high_pct": -17.8,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1283,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-27",
        "signal_date": "2022-10-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.5,
        "current_return_pct": 39.47,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1172,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-28",
        "signal_date": "2022-10-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.5,
        "current_return_pct": 44.12,
        "best_rally_pct": 71.57,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1171,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-31",
        "signal_date": "2022-10-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.5,
        "current_return_pct": 39.47,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1168,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-13",
        "signal_date": "2022-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.8,
        "current_price": 10.5,
        "current_return_pct": 54.41,
        "best_rally_pct": 83.82,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1125,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-14",
        "signal_date": "2022-12-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9214,
        "current_price": 10.5,
        "current_return_pct": 51.7,
        "best_rally_pct": 80.6,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1124,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-19",
        "signal_date": "2022-12-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9,
        "current_price": 10.5,
        "current_return_pct": 52.17,
        "best_rally_pct": 81.16,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1119,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-05",
        "signal_date": "2023-01-05",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.6,
        "current_price": 10.5,
        "current_return_pct": 59.09,
        "best_rally_pct": 89.39,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1102,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-06",
        "signal_date": "2023-01-06",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.5,
        "current_price": 10.5,
        "current_return_pct": 61.54,
        "best_rally_pct": 92.31,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -16.0,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 1101,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-02-27",
        "signal_date": "2024-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.42,
        "current_price": 10.5,
        "current_return_pct": 333.88,
        "best_rally_pct": 387.6,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 4,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 684,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-02",
        "signal_date": "2024-04-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.0,
        "current_price": 10.5,
        "current_return_pct": 425.0,
        "best_rally_pct": 490.0,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 649,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-03",
        "signal_date": "2024-04-03",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.9,
        "current_price": 10.5,
        "current_return_pct": 452.63,
        "best_rally_pct": 521.05,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 648,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.775,
        "current_price": 10.5,
        "current_return_pct": 491.55,
        "best_rally_pct": 564.79,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 647,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-05",
        "signal_date": "2024-04-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.5,
        "current_return_pct": 517.65,
        "best_rally_pct": 594.12,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 646,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.5,
        "current_return_pct": 517.65,
        "best_rally_pct": 594.12,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 643,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 10.5,
        "current_return_pct": 536.36,
        "best_rally_pct": 615.15,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 642,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-12",
        "signal_date": "2024-04-12",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.5,
        "current_return_pct": 588.52,
        "best_rally_pct": 673.77,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 639,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-16",
        "signal_date": "2024-04-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.5,
        "current_return_pct": 588.52,
        "best_rally_pct": 673.77,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 635,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-17",
        "signal_date": "2024-04-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.48,
        "current_price": 10.5,
        "current_return_pct": 609.46,
        "best_rally_pct": 697.3,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 634,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-25",
        "signal_date": "2024-04-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.225,
        "current_price": 10.5,
        "current_return_pct": 757.14,
        "best_rally_pct": 863.27,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 626,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-26",
        "signal_date": "2024-04-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.35,
        "current_price": 10.5,
        "current_return_pct": 677.78,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 625,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-29",
        "signal_date": "2024-04-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.5,
        "current_return_pct": 677.78,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 622,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.5,
        "current_return_pct": 677.78,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 621,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-07-15",
        "signal_date": "2024-07-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.6,
        "current_price": 10.5,
        "current_return_pct": 556.25,
        "best_rally_pct": 637.5,
        "best_rally_date": "2025-12-03",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -11.02,
        "days_since_last_high": 24,
        "lock_in_reached": true,
        "age_days": 545,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 411.07,
      "median_rally_pct": 470.76,
      "best_rally_pct": 920.41,
      "worst_rally_pct": 70.68
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-11 18:23:05 UTC"
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 60/100 indicates strong opportunity quality",
      "Timing regime: CROWDED",
      "Historical profile: 1 rallies, 638% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "STX.L",
      "latest": [
        {
          "title": "Block listing 6 Monthly Return",
          "announcement_date": "2nd Jan 2026",
          "release_time": "11:06 am",
          "source": "RNS",
          "content": "2 Jan 2026 11:06\nRNS Number : 4870N\nShield Therapeutics PLC\n02 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBlock Listing 6 Monthly Return\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n39,794\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n39,794\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics plc 2016 Company Share Option Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n341,020\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n341,020\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nThe Shield Therapeutics plc 2016 Long Term Incentive Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n24,273\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n24,273\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention and Performance Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n2,870,838\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n15,000,000\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\n6,137,791\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n11,733,071\nName of contact:\nLucy Huntington-Bailey\nTelephone number of contact:\n+44 (0) 191 511 8500\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n+44 (0) 191 511 8500\ninfo@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christoper Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLREAFFAEESKEFA"
        },
        {
          "title": "Total Voting Rights",
          "announcement_date": "1st Oct 2025",
          "release_time": "8:00 am",
          "source": "RNS",
          "content": "1 Oct 2025 08:00\nRNS Number : 5071B\nShield Therapeutics PLC\n01 October 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 01 October, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 1,061,802,812 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPURGBUPAGBU"
        },
        {
          "title": "Total Voting Rights",
          "announcement_date": "1st Oct 2025",
          "release_time": "8:00 am",
          "source": "RNS",
          "content": "1 Oct 2025 08:00\nRNS Number : 5071B\nShield Therapeutics PLC\n01 October 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 01 October, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 1,061,802,812 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPURGBUPAGBU"
        },
        {
          "title": "FDA approves extension for ACCRUFeR\u00ae",
          "announcement_date": "22nd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "22 Dec 2025 07:00\nRNS Number : 3781M\nShield Therapeutics PLC\n22 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA approves extension of the indication for ACCRUFeR\u00ae to includechildren 10 years and older with iron deficiency (ID)\nLondon, UK, 22 December 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA), following a priority review of the clinical supplement, has approved the extension of the indication for ACCRUFeR\u00ae (ferric maltol) to include adolescents. ACCRUFeR\u00ae is now indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nAnders Lundstrom, CEO of Shield, commented:\n\"We are delighted with the FDA approval of ACCRUFeR\u00ae, making it available to the adolescent population, who now can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is the final study in the comprehensive paediatric development program that Shield committed to implement with both the European EMA and the US FDA.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nREABCBDDSUDDGUB"
        },
        {
          "title": "FDA approves extension for ACCRUFeR\u00ae",
          "announcement_date": "22nd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "22 Dec 2025 07:00\nRNS Number : 3781M\nShield Therapeutics PLC\n22 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA approves extension of the indication for ACCRUFeR\u00ae to includechildren 10 years and older with iron deficiency (ID)\nLondon, UK, 22 December 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA), following a priority review of the clinical supplement, has approved the extension of the indication for ACCRUFeR\u00ae (ferric maltol) to include adolescents. ACCRUFeR\u00ae is now indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nAnders Lundstrom, CEO of Shield, commented:\n\"We are delighted with the FDA approval of ACCRUFeR\u00ae, making it available to the adolescent population, who now can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is the final study in the comprehensive paediatric development program that Shield committed to implement with both the European EMA and the US FDA.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nREABCBDDSUDDGUB"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 375,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 230.0,
      "trend_direction": "UP",
      "intelligence_signal": "DEAD_TICKER",
      "activity_level": "DEAD"
    },
    "volatility": {
      "atr_normalized": null,
      "stddev_20d": null
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=87.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +16 (best_rally_pct=638%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 87.55,
      "reason": "Drawdown of 87.5% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 16,
      "best_rally_pct": 637.5,
      "reason": "Best rally of 638% gives 16/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Historically strong runner - massive upside when it moves",
        "tag": "HIGH",
        "evidence": [
          "best_rally_pct=638%",
          "Rally_Count=1.0"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Triangulation not loaded (RNS/social/trends missing)",
        "tag": "HIGH",
        "evidence": [
          "analysis_mode=HISTORICAL_ONLY",
          "confidence_capped_at_65"
        ]
      },
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "SELL/TAKE_PROFITS",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CROWDED",
    "run_multiple": 0.87,
    "current_run_pct": 556.25,
    "avg_historical_run_pct": 637.5
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CROWDED timing with 60/100 APEX score. Historical data shows 1 rallies averaging 638% upside. Current position: +556.2%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Strong historical rally behavior (638% best run)"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Late stage. Consider taking profits as risk/reward deteriorates.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": false,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}